The Butantan Institute is continuing its clinical study of a dengue vaccine for elderly populations following a temporary suspension, according to reports from Folha de S.Paulo and CNN Brasil. The institute’s director stated the pause was necessary to ensure a rigorous investigation into the immunizer’s safety and efficacy before resuming the trial.
Why was the elderly vaccine study paused?
The Butantan Institute implemented a temporary suspension of its dengue vaccine study specifically targeting elderly participants to conduct a detailed internal investigation, according to CNN Brasil. The director of the institute defended the move, stating that maintaining scientific rigor during the investigation process is essential to guarantee the safety of the participants and the integrity of the results.
While the study faced a temporary halt, the institute has since moved forward with the research, according to Folha de S.Paulo.
Is the dengue vaccine still available to the public?
Yes. Despite the temporary suspension of the specific study for the elderly, vaccination against dengue remains available through the public health network, according to G1. The general immunization campaign for approved age groups continues without interruption, distinguishing the ongoing public health rollout from the specific clinical trial conducted by Butantan.
How is misinformation impacting public health efforts?
Public health advocates and officials are warning that disinformation is actively hindering vaccination rates in Brazil. In a statement attributed to the Partido dos Trabalhadores, officials described misinformation as a “powerful virus” that attacks the health of the Brazilian population.
Addressing the Legislative Assembly of Piauí, Dr. Hélio advocated for the continued use of vaccines, emphasizing their importance in controlling the disease even as the government navigates decisions regarding specific immunizers.
